Neoadjuvant chemotherapy for breast cancer

Area of Science:

• Oncology
• Chemotherapy
• Breast Cancer Research

Background:

• Neoadjuvant chemotherapy in early breast cancer serves as an in vivo assessment of treatment efficacy.
• It offers potential for tumor downstaging and avoiding mastectomy.

Purpose of the Study:

• To evaluate the role and effectiveness of neoadjuvant chemotherapy in early breast cancer.
• To explore tumor response as a surrogate for treatment outcome and micrometastatic disease impact.

Main Methods:

• Review of randomized studies comparing preoperative and postoperative chemotherapy.
• Analysis of reported overall and complete clinical response rates.
• Evaluation of pathological complete remission as a prognostic indicator.

Main Results:

• Preoperative chemotherapy is as effective as postoperative chemotherapy.
• Response rates vary widely (60-100%), with significant rates of mastectomy avoidance (10-50% complete clinical response).
• Clinical responders show better prognosis; pathological complete remission predicts good outcome but occurs in <20% of patients.

Conclusions:

• Neoadjuvant chemotherapy demonstrates efficacy in early breast cancer, enabling tumor response evaluation and mastectomy avoidance.
• While current survival benefits are not significantly increased, pathological complete remission is a strong predictor of long-term outcome.
• Future research focuses on biological predictors of response for improved surrogate markers.